Added to YB: 2025-02-26
Pitch date: 2025-02-24
STOK [bullish]
Stoke Therapeutics, Inc.
+306.26%
current return
Author Info
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression.
Market Cap
$1.8B
Pitch Price
$8.46
Price Target
20.20 (-41%)
Dividend
N/A
EV/EBITDA
48.06
P/E
46.60
EV/Sales
7.29
Sector
Biotechnology
Category
value
Show full summary:
Weekend thoughts: Opportunities in small biopharma
STOK: Trading at $8.33, just $1/share above $385M net cash. Biogen deal values ex-US rights at ~$500M NPV. US rights est. worth $350M. Total asset value ~$20.20/share. Phase 3 trial risk, but Biogen partnership validates potential. Sector-wide biotech undervaluation opportunity.
Read full article (7 min)